

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/003061

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/057716 A (BOERTH NANCY JOHNSTON ; NEW RIVER PHARMACEUTICALS INC (US); BISHOP BAR) 17 July 2003 (2003-07-17) page 7 - page 8; claims 10,11; figures 3-5 page 5, paragraph 2	1,2,4, 10-13, 21-25, 32, 34-36, 74-88
X	WO 02/083180 A (BEUSKER PATRICK HENRY ; BUSSCHER GUUSKE FREDRIKE (NL); SCHEEREN JOHAN) 24 October 2002 (2002-10-24) cited in the application page 10, lines 25-28; claims 13,14; figures 3,12	1,2,4, 10-12, 20-25, 32-36, 40-72, 74-88
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 February 2006

Date of mailing of the international search report

26. 05. 2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

González Ramon, N.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/003061

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2004/019993 A (LIST BENJAMIN ; PESSAH NETA (IL); SHAMIS MARINA (IL); AMIR ROEY JACOB) 11 March 2004 (2004-03-11) cited in the application</p> <p>page 5; figure 3; compound 1B page 25, line 12 - page 26, line 10 page 32, lines 6-16; claims 3,7,13,16,24,123,129,161</p>	<p>1,2,4, 10-12, 20-25, 27-36, 40-72, 74-88</p>
X	<p>SHABAT D. ET AL: "Chemical adaptor systems" CHEM. EUR. J., vol. 10, 22 March 2004 (2004-03-22), XP002298470 cited in the application see conclusions abstract; figures 1,2,8</p>	<p>1,2,4, 10-12, 20-25, 27-36, 40-72, 74-88</p>
P,X	<p>WO 2004/043493 A (BEUSKER PATRICK HENRY ; SCHEEREN JOHANNES WILHELM (NL); SYNTARGA B V () 27 May 2004 (2004-05-27) cited in the application</p> <p>page 34, lines 18-20; claims 42,49 page 41, line 10 - page 42, line 28 page 50, line 29 - page 51, line 25 page 12, paragraph 3 page 14, paragraphs 1,2</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
Y	<p>AMIR R. J. ET AL: "Self immolative dendrimers" ANGEW. CHEM. INT., vol. 42, 2003, pages 4494-4499, XP008035926 abstract; figure 1</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
Y	<p>SAUERBREI B. ET AL: "An enzyme labile linker group for organic syntheses on solid supports" ANGEW. CHEM. INT. ED, vol. 37, 1998, pages 1143-1146, XP001120792 page 1144, paragraph 2; figure 1</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/003061

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GROOT DE FRANCISCUS M H ET AL: "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatable Anticancer Prodrugs for Enhanced Drug Release"</p> <p>JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 66, 2001, pages 8815-8830, XP002212035</p> <p>ISSN: 0022-3263</p> <p>abstract; figure 1</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
A	<p>GREENWALD R B ET AL: "Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, September 1999 (1999-09), pages 3657-3667, XP002184836</p> <p>ISSN: 0022-2623</p> <p>cited in the application</p> <p>figures 2,8</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
A	<p>ANTCZAK C ET AL: "A NEW ACIVICIN PRODRUG DESIGNED FOR TUMOR-TARGETED DELIVERY"</p> <p>BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 9, 2001, pages 2843-2848, XP001150714</p> <p>ISSN: 0968-0896</p> <p>cited in the application</p> <p>abstract</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
X	<p>WO 03/026577 A (SEATTLE GENETICS, INC; SENTER, PETER, D; TOKI, BRIAN, E)</p> <p>3 April 2003 (2003-04-03)</p> <p>page 16, lines 8-31</p> <p>pages 6,7; claims 37-44,79,93</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>
E	<p>EP 1 525 890 A (COMPLEX BIOSYSTEMS GMBH)</p> <p>27 April 2005 (2005-04-27)</p> <p>page 69</p> <p>page 71 - page 72</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/003061

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 2005/082023 A (GENENTECH, INC; SEATTLE GENETICS, INC; FENG, BAINIAN) 9 September 2005 (2005-09-09)</p> <p>abstract; claims 4,5,34,35; figure 1 -----</p>	<p>1,2,4, 10-13, 20-25, 27-36, 40-72, 74-88</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/003061

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 76-88 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see annex

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1,2, 4, 10-13, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a polymer as recited in claim 13 and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 2-31

2. claims: 1,2, 4-9, 12, 13, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a polymer as recited in claim 13 and T is protein or polypeptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1, 3-31

3. claims: 1, 2, 4, 5, 12, 13, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a polymer as recited in claim 13 and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1, 2, 4-31

4. claims: 1, 2, 4, 10-12, 14, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is an hydrogel and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-3, 5-31

5. claims: 1, 2, 4-9, 12, 14, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a hydrogel and T is a protein or peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-4, 6-31

6. claims: 1, 2, 4, 5, 12, 14, 20-25, 27-36, 40-72, 74-88 in part

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is an hydrogel and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-5, 7-31

7. claims: 1, 2, 4, 10-12, 15, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a branched or hyperbranched polymer and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-6, 8-31

8. claims: 1, 2, 4-9, 12, 15, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a branched or hyperbranched polymer and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-7, 9-31

9. claims: 1,2, 4, 5, 12, 15, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a branched or hyperbranched polymer and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-8, 10-31

10. claims: 1, 2, 4, 10-12, 16, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a dendrimer or dense star polymer and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-9, 11-31.

11. claims: 1, 2, 4-9, 12, 16, 20-25, 27-36, 40-72, 74-88 in part

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a dendrimer or dense star polymer and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-10, 12-31

12. claims: 1, 2, 4, 5, 12, 16, 20-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a dendrimer or dense star polymer and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-11, 13-31

13. claims: 1, 2, 4, 10-12, 17-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a biopolymer or a protein and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-12, 14-31.

14. claims: 1,2, 4-9, 12, 17-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a biopolymer or protein and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-13, 15-31

15. claims: 1, 2, 4, 5, 12, 17-25, 27-36, 40-72, 74-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 2 wherein R1 is a biopolymer or a protein and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-14, 16-31

16. claims: 1, 3, 4, 10-13, 20-25, 27-36, 40-88 in part

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a polymer as recited in claim 13 and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-15, 17-31

17. claims: 1, 3-9, 12, 13, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a polymer as recited in claim 13 and T is protein or polypeptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-16, 18-31

18. claims: 1, 3-5, 12, 13, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a polymer as recited in claim 13 and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-17, 19-31

19. claims: 1, 3, 4, 10-12, 14, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is an hydrogel and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-18, 20-31

20. claims: 1, 3-9, 12, 14, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a hydrogel and T is a protein or peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-19, 21-31

21. claims: 1, 3-5, 12, 14, 20-25, 27-36, 40-88 in part

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is an hydrogel and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-20, 22-31

22. claims: 1, 3, 4, 10-12, 15, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a branched or hyperbranched polymer and T is a biologically active small molecule. Excluding the subject matter of inventions 1-21, 23-31

23. claims: 1, 3-9, 12, 15, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a branched or hyperbranched polymer and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-22, 24-31

24. claims: 1, 3-5, 12, 15, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a branched or hyperbranched polymer and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-23, 25-31

25. claims: 1, 3, 4, 10-12, 16, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a dendrimer or dense star polymer and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-24, 26-31

26. claims: 1, 3-9, 12, 16, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a dendrimer or dense star polymer and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-25, 27-31

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

27. claims: 1, 3-5, 12, 16, 20-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a dendrimer or dense star polymer and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-26, 28-31

28. claims: 1, 3, 4, 10-12, 17-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a biopolymer or a protein and T is a biologically active small molecule. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-27, 29-31

29. claims: 1, 3-9, 12, 17-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a biopolymer or protein and T is a protein or a peptide. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-28, 30-31

30. claims: 1,3-5, 12, 17-25, 27-36, 40-88 in part

Polymeric cascade prodrug having the structure as depicted by claim 3 wherein R1 is a biopolymer or a protein and T is an oligonucleotide or peptide nucleic acid. Method of administration of the same comprising cleavage from the carrier by means of a non-enzymatic reaction. Excluding the subject matter of inventions 1-29, 31

31. claims: 26, 37-39 complete; 1-3, 12-25, 27-36, 40-52, 54, 55, 60-62, 64-71 in part

Molecule having the structure as depicted by claims 2 or 3 wherein R1 is a polymer and T is leaving group A. Excluding the subject matter of inventions 1-30

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/003061

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03057716	A	17-07-2003	AU 2003210454 A1 CA 2472917 A1	24-07-2003 17-07-2003
WO 02083180	A	24-10-2002	CA 2441597 A1 CN 1511044 A EP 1243276 A1 JP 2004530670 T NZ 528414 A US 2004121940 A1	24-10-2002 07-07-2004 25-09-2002 07-10-2004 29-04-2005 24-06-2004
WO 2004019993	A	11-03-2004	AU 2003256038 A1	19-03-2004
WO 2004043493	A	27-05-2004	AU 2003282624 A1 CA 2506080 A1 EP 1560599 A1 JP 2006507322 T	03-06-2004 27-05-2004 10-08-2005 02-03-2006
WO 03026577	A	03-04-2003	NONE	
EP 1525890	A	27-04-2005	WO 2005034909 A2	21-04-2005
WO 2005082023	A	09-09-2005	NONE	